Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/23421
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hissaria, P. | - |
dc.contributor.author | Smith, W. | - |
dc.contributor.author | Wormald, P. | - |
dc.contributor.author | Taylor, J. | - |
dc.contributor.author | Vadas, M. | - |
dc.contributor.author | Gillis, D. | - |
dc.contributor.author | Kette, F. | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Journal of Allergy and Clinical Immunology, 2006; 118(1):128-133 | - |
dc.identifier.issn | 0091-6749 | - |
dc.identifier.issn | 1097-6825 | - |
dc.identifier.uri | http://hdl.handle.net/2440/23421 | - |
dc.description.abstract | Background: Topical and systemic corticosteroids are the first choice in medical treatments for sinonasal polyposis, but surprisingly, there is no high-level evidence for the efficacy of oral corticosteroids. Objective: The aim of this study was to establish the efficacy of a short course of oral prednisolone in ameliorating the symptoms of sinonasal polyposis, as well as reducing mucosal inflammation assessed by means of nasendoscopy and magnetic resonance imaging (MRI). A secondary aim was to evaluate the relationship between outcome measures. Methods: Subjects with symptomatic endoscopically diagnosed sinonasal polyposis received 50 mg of prednisolone daily for 14 days or placebo. Outcome was quantified by using the modified 31-item Rhinosinusitis Outcome Measure questionnaire, physician's assessment, nasendoscopy with photography, and MRI. Results: There were 20 subjects in each treatment group. Only the prednisolone-treated group showed significant improvement in nasal symptoms (P < .001). The Rhinosinusitis Outcome Measure score improved in both groups, but the prednisolone-treated group had significantly greater improvement than the placebo group (P < .001). Objectively, there was significant reduction in polyp size, as noted with nasendoscopy (P < .001) and MRI (P < .001), only in the prednisolone-treated group. The outcome measures correlated with each other; the highest level of correlation was between the objective measures of nasendoscopy and MRI (R2 = 0.76, P < .001). There were no significant adverse events. Conclusion: This trial clearly establishes clinically significant improvement in the symptoms and pathology of sinonasal polyposis with a short course of systemic corticosteroids. MRI scanning and quantitative nasendoscopic photography are objective and valid tools for assessing the outcome of treatment in this condition. Clinical implications: A 14-day course of 50 mg of prednisolone is safe and effective therapy for symptomatic nasal polyposis. | - |
dc.description.statementofresponsibility | Pravin Hissaria, William Smith, Peter J. Wormald, James Taylor, Mathew Vadas, David Gillis and Frank Kette | - |
dc.language.iso | en | - |
dc.publisher | Mosby Inc | - |
dc.source.uri | http://dx.doi.org/10.1016/j.jaci.2006.03.012 | - |
dc.subject | Nasal polyps | - |
dc.subject | corticosteroids | - |
dc.subject | medical treatment | - |
dc.subject | 31-item rhinosinusitis outcome measure | - |
dc.subject | endoscopy | - |
dc.subject | magnetic resonance imaging | - |
dc.subject | outcome | - |
dc.subject | randomized | - |
dc.subject | double blind | - |
dc.subject | placebo controlled | - |
dc.title | Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.jaci.2006.03.012 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Wormald, P. [0000-0001-7753-7277] | - |
Appears in Collections: | Aurora harvest 2 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.